

**Supplemental Table 1: Clinical information of iris melanoma patients**

No.	Diagnose	Age	Sex	Site	Gene mutations	Clinical info
7	<i>Iris-MM</i>	70	F	OD	GNAQ	Follow-up: 43 months; therapy: proton radiotherapy; no relapse; no metastasis
8	<i>Iris-MM</i>	91	F	OD	GNAQ	Follow-up: 12 months; therapy: brachytherapy; no relapses; no metastasis
9	<i>Iris-MM</i>	81	M	OS	GNAQ; EIF1AX; IHC: BAP1-	Follow-up: 2 months; patients refused proton radiotherapy; no relapse; no metastasis
10	<i>Iris-MM</i>	79	M	OD	GNA11; EIF1AX	Follow-up: 15 months; therapy: proton radiotherapy; no relapse; no metastasis
11	<i>Iris-MM</i>	74	F	OS	GNAQ; EIF1AX	Follow-up: 30 months; therapy: proton radiotherapy; no relapses; no metastasis
12	<i>Iris-MM</i>	70	M	OD	GNA11; EIF1AX	Follow-up: 20 months; therapy: proton radiotherapy; no relapses; no metastasis
13	<i>Iris-MM</i>	65	F	OD	No mutation	Follow-up: 89 months; therapy: proton radiotherapy; no relapses; no metastasis
14	<i>Iris-MM</i>	78	M	OD	GNA11; EIF1AX	Follow-up: 14 months; therapy: brachytherapy; no relapses; no metastasis
15	<i>Iris-MM</i>	66	M	OD	GNAQ	Follow-up: 66 months; therapy: brachytherapy; no relapses; no metastasis
16	<i>Iris-MM</i>	43	F	OD	No mutation	Follow-up: 23 months; therapy: proton radiotherapy; no relapses; no metastasis
17	<i>Iris-MM</i>	27	M	OS	GNAQ	Follow-up: 15 months; therapy: brachytherapy; no relapses; no metastasis
18	<i>Iris-MM</i>	62	F	OS	No mutation	Follow-up: 8 months; therapy: proton radiotherapy; no relapses; no metastasis
19	<i>Iris-MM</i>	74	M	OD	GNAQ; EIF1AX	No follow-up; patient refuses to get any treatment at all
20	<i>Iris-MM</i>	48	F	OS	GNAQ	Follow-up: 6 months; therapy: brachytherapy; no relapses; no metastasis
21	<i>Iris-MM</i>	39	F	OS	GNAQ	Follow-up: 14 months; therapy: proton radiotherapy; no relapses; no metastasis
22	<i>Iris-MM</i>	82	M	OS	GNAQ	Follow-up: 84 months; therapy: proton radiotherapy; no relapses; no metastasis
23	<i>Iris-MM</i>	73	M	OD	GNAQ; EIF1AX	Follow-up: 13 months; therapy: proton radiotherapy; developed local relapse after 7 months, followed by enucleation; no metastasis; Monosomie 3 identified
24	<i>Iris-MM</i>	33	M	OS	GNAQ	Follow-up: 18 months; patients refused to get any treatment at all; no relapses; no metastasis
25	<i>Iris-MM</i>	60	F	OD	GNAQ; EIF1AX	Follow-up: 23 months; therapy: proton radiotherapy; developed secondary glaucoma, followed by enucleation after 1 year; no relapses; no metastasis

MM = malignant melanoma; M = male; F = female; OS = oculus sinistra, OD = oculus dextra.